Assessment of lipocalin 2, clusterin, soluble tumor necrosis factor receptor-1, interleukin-6, homocysteine, and uric acid levels in patients with psoriasis

Disease Markers

Volumn 2014, Issue , 2014, Pages

  Ataseven, Arzu ^a   Kesli, Recep ^b   Kurtipek, Gulcan Saylam ^a   Ozturk, Perihan ^c  

^a Konya Training and Research Hospital ^*  (Turkey)

^b AFYON KOCATEPE UNIVERSITY   (Turkey)

^c KAHRAMANMARAS SUTCU IMAM UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CLUSTERIN; HOMOCYSTEINE; INTERLEUKIN 6; LIPOCALIN; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; TUMOR NECROSIS FACTOR RECEPTOR 1; URIC ACID; ACUTE PHASE PROTEIN; BIOLOGICAL MARKER; CLU PROTEIN, HUMAN; IL6 PROTEIN, HUMAN; LCN2 PROTEIN, HUMAN; ONCOPROTEIN;

ADULT; ARTICLE; BODY MASS; CHRONIC INFLAMMATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; URIC ACID BLOOD LEVEL; BLOOD; CASE CONTROL STUDY; YOUNG ADULT;

ACUTE-PHASE PROTEINS; ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CLUSTERIN; FEMALE; HOMOCYSTEINE; HUMANS; INTERLEUKIN-6; LIPOCALINS; MALE; PROTO-ONCOGENE PROTEINS; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; URIC ACID; YOUNG ADULT;

EID: 84899411063     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2014/541709     Document Type: Article

References (60)

1. Ceyhan A. M., Yildirim M., Ceyhan B. M., Sütçü R., Serum neopterin and TNF- α levels in psoriasis and their correlation with disease severity. Turkderm Deri Hastaliklari ve Frengi Arsivi 2012 46 1 7 10 2-s2.0-84859630765 10.4274/turkderm.60243
2. Kamata M., Tada Y., Tatsuta A., Kawashima T., Shibata S., Mitsui H., Asano Y., Sugaya M., Kadono T., Kanda N., Watanabe S., Sato S., Serum lipocalin-2 levels are increased in patients with psoriasis. Clinical and Experimental Dermatology 2012 37 3 296 299 2-s2.0-84858442372 10.1111/j.1365-2230.2011.04265.x
3. Flo T. H., Smith K. D., Sato S., Rodriguez D. J., Holmes M. A., Strong R. K., Akira S., Aderem A., Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature 2004 432 7019 917 921 2-s2.0-11144314814 10.1038/nature03104
4. Cowland J. B., Borregaard N., Molecular characterization and pattern of tissue expression of the gene for neutrophil gelatinase-associated lipocalin from humans. Genomics 1997 45 1 17 23 2-s2.0-0031260224 10.1006/geno.1997.4896
5. Chakraborty S., Kaur S., Guha S., Batra S. K., The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer. Biochimica et Biophysica Acta 2012 1826 1 129 169 2-s2.0-84860222365 10.1016/j.bbcan.2012.03.008
6. Calero M., Rostagno A., Frangione B., Ghiso J., Clusterin and Alzheimer's disease. Sub-Cellular Biochemistry 2005 38 273 298 2-s2.0-15944363808
7. Nuutinen T., Suuronen T., Kauppinen A., Salminen A., Valproic acid stimulates clusterin expression in human astrocytes: Implications for Alzheimer's disease. Neuroscience Letters 2010 475 2 64 68 2-s2.0-77952888035 10.1016/j.neulet.2010.03.041
8. Falgarone G., Chiocchia G., Chapter 8: clusterin: a multifacet protein at the crossroad of inflammation and autoimmunity. Advances in Cancer Research 2009 104 139 170 2-s2.0-73949151645
9. Rothe J., Gehr G., Loetscher H., Lesslauer W., Tumor necrosis factor receptors-structure and function. Immunologic Research 1992 11 2 81 90 2-s2.0-0026673687
10. Kinloch R. D., Lee C. M., van Rooijen N., Morgan E. T., Selective role for tumor necrosis factor- α but not interleukin-1 or Kupffer cells, in down-regulation of CYP3A11 and CYP3A25 in livers of mice infected with a noninvasive intestinal pathogen. Biochemical Pharmacology 2011 82 3 312 321 2-s2.0-79959552379 10.1016/j.bcp.2011.04.016
11. Kumari S., Bonnet M. C., Ulvmar M. H., Tumor necrosis factor receptor signaling in keratinocytes triggers interleukin-24-dependent psoriasis like skin inflammation in mice. Immunity 2013 39 899 911
12. Castells-Rodellas A., Castell J. V., Ramirez-Bosca A., Nicolas J. F., Valcuende-Cavero F., Thivolet J., Interleukin-6 in normal skin and psoriasis. Acta Dermato-Venereologica 1992 72 3 165 168 2-s2.0-0026587563
13. van Snick J., Interleukin-6: An overview. Annual Review of Immunology 1990 8 253 278 2-s2.0-0025260903
14. Sehgal P. B., Interleukin-6: molecular pathophysiology. Journal of Investigative Dermatology 1990 94 2S 6S 2-s2.0-0025363091
15. Fattori E., Cappelletti M., Costa P., Sellitto C., Cantoni L., Carelli M., Faggioni R., Fantuzzi G., Ghezzi P., Poli V., Defective inflammatory response in interleukin 6-deficient mice. Journal of Experimental Medicine 1994 180 4 1243 1250 2-s2.0-0027984754
16. Martí-Carvajal A. J., Solà I., Lathyris D., Salanti G., Homocysteine lowering interventions for preventing cardiovascular events. Cochrane Database of Systematic Reviews 2009 4 10.1002/14651858.CD006612.pub2 2-s2.0-75349104437
17. Selhub J., Homocysteine metabolism. Annual Review of Nutrition 1999 19 217 246 2-s2.0-0032771346 10.1146/annurev.nutr.19.1.217
18. Brian Boudi F., Noncoronary atherosclerosis overview of atherosclerosis. Medscape 2013
19. Brazzelli V., Grasso V., Fornara L., Moggio E., Gamba G., Villani S., Borroni G., Homocysteine, vitamin B12 and folic acid levels in psoriatic patients and correlation with disease severity. International Journal of Immunopathology and Pharmacology 2010 23 3 911 916 2-s2.0-78149257221
20. McCrudden F. H., Uric Acid 2008 BiblioBazaar
21. Romani J., Caixas A., Ceperuelo-Mallafre V., Circulating levels of lipocalin-2 and retinol-binding protein-4 are increased in psoriatic patients and correlated with baseline PASI. Archives of Dermatological Research 2013 305 105 112
22. El-Hadidi H., Samir N., Shaker O. G., Otb S., Estimation of tissue and serum lipocalin-2 in psoriasis vulgaris and its relation to metabolic syndrome. Archives of Dermatological Research 2014 306 3 239 45
23. Guttman-Yassky E., Lowes M. A., Fuentes-Duculan J., Zaba L. C., Cardinale I., Nograles K. E., Khatcherian A., Novitskaya I., Carucci J. A., Bergman R., Krueger J. G., Low expression of the IL-23/Th17 pathway in atopic dermatitis compared to psoriasis. Journal of Immunology 2008 181 10 7420 7427 2-s2.0-58149198187
24. Shen F., Hu Z., Goswami J., Gaffen S. L., Identification of common transcriptional regulatory elements in interleukin-17 target genes. Journal of Biological Chemistry 2006 281 34 24138 24148 2-s2.0-33747662347 10.1074/jbc.M604597200
25. Lee J. H., Kye K. C., Seo E. Y., Lee K., Lee S. K., Lim J. S., Seo Y. J., Chang D. K., Park J. K., Expression of neutrophil gelatinase-associated lipocalin in calcium-induced keratinocyte differentiation. Journal of Korean Medical Science 2008 23 2 302 306 2-s2.0-43449108589 10.3346/jkms.2008.23.2.302
26. Seo S. J., Ahn J. Y., Hong C. K., Seo E. Y., Kye K. C., Lee W. H., Lee S. K., Lim J. S., Hahn M. J., Kjeldsen L., Borregaard N., Kim C. D., Park J. K., Lee J. H., Expression of neutrophil gelatinase-associated lipocalin in skin epidermis. Journal of Investigative Dermatology 2006 126 2 510 512 2-s2.0-33644650952 10.1038/sj.jid.5700035
27. Mallbris L., O'Brien K. P., Hulthén A., Sandstedt B., Cowland J. B., Borregaard N., Ståhle-Bäckdahl M., Neutrophil gelatinase-associated lipocalin is a marker for dysregulated keratinocyte differentiation in human skin. Experimental Dermatology 2002 11 6 584 591 2-s2.0-0038154452 10.1034/j.1600-0625.2002.110611.x
28. Stejskal D., Karpíšek M., Humenanska V., Hanulova Z., Stejskal P., Kusnierova P., Petzel M., Lipocalin-2: development, analytical characterization, and clinical testing of a new ELISA. Hormone and Metabolic Research 2008 40 6 381 385 2-s2.0-47049118231 10.1055/s-2008-1062746
29. Wu G., Li H., Zhou M., Fang Q., Bao Y., Xu A., Jia W., Mechanism and clinical evidence of lipocalin-2 and adipocyte fatty acid-binding protein linking obesity and atherosclerosis. Diabetes Metabolism Research and Reviews 2013 10.1002/dmrr.2493
30. Xiao Y., Xu A., Hui X., Circulating lipocalin-2 and retinol-binding protein 4 are associated with intima-media thickness and subclinical atherosclerosis in patients with type 2 diabetes. PLoS ONE 2013 8 e66607
31. Garcia-Rodriguez S., Arias-Santiago S., Perandres-Lopez R., Decreased plasma levels of clusterin in patients with psoriasis. Actas Dermosifiliogr 2013 104 497 503
32. McLaughlin L., Zhu G., Mistry M., Ley-Ebert C., Stuart W. D., Florio C. J., Groen P. A., Witt S. A., Kimball T. R., Witte A. P., Harmony J. A. K., Aronow B. J., Apolipoprotein J/clusterin limits the severity of murine autoimmune myocarditis. Journal of Clinical Investigation 2000 106 9 1105 1113 2-s2.0-0033756826
33. Devauchelle V., Essabbani A., de Pinieux G., Germain S., Tourneur L., Mistou S., Margottin-Goguet F., Anract P., Migaud H., le Nen D., Lequerré T., Saraux A., Dougados M., Breban M., Fournier C., Chiocchia G., Characterization and functional consequences of underexpression of clusterin in rheumatoid arthritis. Journal of Immunology 2006 177 9 6471 6479 2-s2.0-33750347516
34. Blumenstein B., Saad F., Hotte S., Chi K. N., Eigl B., Gleave M., Jacobs C., Reduction in serum clusterin is a potential therapeutic biomarker in patients with castration-resistant prostate cancer treated with custirsen. Cancer Medicine 2013 2 468 477
35. Fandridis E., Apergis G., Korres D. S., Nikolopoulos K., Zoubos A. B., Papassideri I., Trougakos I. P., Increased expression levels of apolipoprotein J/clusterin during primary osteoarthritis. In Vivo 2011 25 5 745 749 2-s2.0-79960629538
36. Wang L., Erling P., Bengtsson A. A., Truedsson L., Sturfelt G., Erlinge D., Transcriptional down-regulation of the platelet ADP receptor P2Y12 and clusterin in patients with systemic lupus erythematosus. Journal of Thrombosis and Haemostasis 2004 2 8 1436 1442 2-s2.0-13244284598 10.1111/j.1538-7836.2004. 00854.x
37. Tobisawa S., Honna M., Ishida-Yamamoto A., Saijo Y., lizuka H., Prognostic factors in 105 Japanese cases of mycosis fungoides and Sezary syndrome: clusterin expression as a novel prognostic factor. Journal of Dermatological Science 2013 71 160 166
38. Yanaba K., Asano Y., Tada Y., Sugaya M., Kadono T., Sato S., A possible contribution of elevated serum clusterin levels to the inhibition of digital ulcers and pulmonary arterial hypertension in systemic sclerosis. Archives of Dermatological Research 2012 304 459 463 2-s2.0-84857026945 10.1007/s00403-012- 1219-3
39. Bettuzzi S., Chapter 1: introduction. Advances in cancer research 2009 104 1 8 2-s2.0-73949140072
40. Serwin A. B., Sokolowska M., Chodynicka B., Soluble tumor necrosis factor α receptor type 1 in psoriasis patients treated with narrowband ultraviolet B. Photodermatology Photoimmunology and Photomedicine 2005 21 4 210 211 2-s2.0-22244472000 10.1111/j.1600-0781.2005.00164.x
41. Brotas A. M., Cunha J. M., Lago E. H., Machado C. C., Carneiro S. C., Tumor necrosis factoralpha and the cytokine network in psoriasis. Anais Brasileiros de Dermatologia 2012 87 673 681
42. Coimbra S., Oliveira H., Reis F., Belo L., Rocha S., Quintanilha A., Figueiredo A., Teixeira F., Castro E., Rocha-Pereira P., Santos-Silva A., Interleukin (IL)-22, IL-17, IL-23, IL-8, vascular endothelial growth factor and tumour necrosis factor- α levels in patients with psoriasis before, during and after psoralen-ultraviolet A and narrowband ultraviolet B therapy. British Journal of Dermatology 2010 163 6 1282 1290 2-s2.0-78649639288 10.1111/j.1365-2133.2010.09992.x
43. Alenius G.-M., Eriksson C., Dahlqvist S. R., Interleukin-6 and soluble interleukin-2 receptor alpha-Markers of inflammation in patients with psoriatic arthritis? Clinical and Experimental Rheumatology 2009 27 1 120 123 2-s2.0-63049139677
44. Koliadenko V. H., Chernyshov P. V., Interleukin-6 as a marker of the activity of a pathological process in patients with psoriasis. Likars'ka Sprava 2005 5-6 80 82 2-s2.0-33644818235
45. Arican O., Aral M., Sasmaz S., Ciragil P., Serum levels of TNF- α IFN- γ IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators of Inflammation 2005 2005 5 273 279 2-s2.0-27644565806 10.1155/MI.2005.273
46. Kaur S., Zilmer K., Kairane C., Kals M., Zilmer M., Clear differences in adiponectin level and glutathione redox status revealed in obese and normal-weight patients with psoriasis. British Journal of Dermatology 2008 159 6 1364 1367 2-s2.0-56549113007 10.1111/j.1365-2133.2008.08759.x
47. Tobin A. M., Hughes R., Hand E. B., Leong T., Graham I. M., Kirby B., Homocysteine status and cardiovascular risk factors in patients with psoriasis: a case-control study. Clinical and Experimental Dermatology 2011 36 1 19 23 2-s2.0-78650111602 10.1111/j.1365-2230.2010.03877.x
48. Malerba M., Gisondi P., Radaeli A., Sala R., Calzavara Pinton P. G., Girolomoni G., Plasma homocysteine and folate levels in patients with chronic plaque psoriasis. British Journal of Dermatology 2006 155 6 1165 1169 2-s2.0-33750925900 10.1111/j.1365-2133.2006.07503.x
49. Vanizor Kural B., Örem A., Çimşit G., Uydu H. A., Yandi Y. E., Alver A., Plasma homocysteine and its relationships with atherothrombotic markers in psoriatic patients. Clinica Chimica Acta 2003 332 1-2 23 30 2-s2.0-0038324408 10.1016/S0009-8981(03)00082-2
50. Refsum H., Helland S., Ueland P. M., Fasting plasma homocysteine as a sensitive parameter of antifolate effect: a study of psoriasis patients receiving low-dose methotrexate treatment. Clinical Pharmacology and Therapeutics 1989 46 5 510 520 2-s2.0-0024351118
51. Karabudak O., Eralp Ulusoy R., Akyol Erikci A., Solmazgul E., Dogan B., Harmanyeri Y., Inflammation and hypercoagulable state in adult psoriatic men. Acta Dermato-Venereologica 2008 88 4 337 340 2-s2.0-47749137845 10.2340/00015555-0456
52. Richetta A. G., Mattozzi C., Macaluso L., Cantisani C., Giancristoforo S., D'epiro S., Salvi M., Scarnò M., Calvieri S., Homocysteine plasmatic status in patients with psoriasis. European Journal of Dermatology 2011 21 4 621 623 2-s2.0-80053024797 10.1684/ejd.2011.1455
53. Cakmak S. K., Gul U., Kilic C., Gonul M., Soylu S., Kilic A., Homocysteine, vitamin B12 and folic acid levels in psoriasis patients. Journal of the European Academy of Dermatology and Venereology 2009 23 300 303
54. Christophers E., Mrowietz U., Fitzpatrick T. B., Freedberg I. M., Eisen A. Z., Wolff K., Austen K. F., Goldsmith L. A., Katz S. I., Psoriasis. Dermatology in General Medicine 2003 6th New York, NY, USA McGraw-Hill 407 427
55. Gisondi P., Targher G., Cagalli A., Girolomoni G., Hyperuricemia in patients with chronic plaque psoriasis. Journal of the American Academy of Dermatology 2014 70 127 130
56. Grzybowski G., Fafara I., Zaba R., Wierusz-Wysocka B., Evaluation of glucose, insulin, C-peptide uric acid serum levels in patients with psoriasis. Polski Merkuriusz Lekarski 2001 11 66 495 498 2-s2.0-0035753015
57. Severin E., Nave B., Ständer M., Ott R., Traupe H., Total antioxidative capacity is normal in sera from psoriasis patients despite elevated bilirubin, tocopherol and urate levels. Dermatology 1999 198 4 336 339 2-s2.0-0032790273 10.1159/000018171
58. Kwon H. H., Kwon I. H., Choi J. W., Youn J. I., Cross-sectional study on the correlation of serum uric acid with disease severity in Korean patients with psoriasis. Clinical and Experimental Dermatology 2011 36 5 473 478 2-s2.0-79959331830 10.1111/j.1365-2230.2010.03988.x
59. Isha I., Jain V. K., Lal H., C-reactive protein and uric acid levels in patients with psoriasis. Indian Journal of Clinical Biochemistry 2011 26 3 309 311 2-s2.0-80052275753 10.1007/s12291-011-0132-4
60. Angelopoulos T. J., Lowndes J., Zukley L., Melanson K. J., Nguyen V., Huffman A., Rippe J. M., The effect of high-fructose corn syrup consumption on triglycerides and uric acid. Journal of Nutrition 2009 139 1242S 1245S 2-s2.0-66749153184 10.3945/jn.108.098194